Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 23

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 23
---
 our competitors have substantially more financial,
technical and personnel resources than us. Most of them also have established brands and substantial experience in the development, production,
regulation, and commercialization of animal health care products. Regarding our development of any new products or technology, we also
compete with academic institutions, governmental agencies and private organizations that conduct research in the field of animal health
medicines. We expect that competition in our industry is based on several factors including primarily product reliability and effectiveness,
product pricing, product branding, adequate patent and other IP protection, safety of use, and product availability.

Although
for the foreseeable future, our efforts and financial resources will continue to focus on successfully commercializing Spryng®, our
future business strategy plan includes the identification of additional animal care products we may license, acquire, or develop, and
then commercializing such products into a branded product portfolio along with Spryng®. Even if we successfully license, acquire
or develop such animal care products from our proprietary technology, or acquire any such new products, we may still fail to commercialize
them successfully for various reasons, including competitors offering alternative products which are more effective than ours, our discovery
of third-party IP rights already covering the products, harmful side effects caused to animals by the products, inability to produce
products in commercial quantities at an acceptable cost, or the products not being accepted by veterinarians and pet owners as being
safe or effective. If we fail to successfully obtain and commercialize future new animal care products, our business and prospects may
be harmed substantially.

We
will rely on third parties to conduct studies of our current and new products, and if these third parties do not successfully perform
their contracted commitments effectively or substantially fail to meet expected study deadlines, we could be delayed from effectively
commercializing our future products.

We
have entered into a clinical trial services agreement with Colorado State University and Ethos Veterinary Health. In the future, we may
engage other educational institutions with a veterinary medical curriculum to conduct studies of Spryng® and other products to be
introduced by us. We expect to have limited control over the timing and resources that such third parties will devote to the studies.
Although we must rely on third parties to conduct our studies, we remain responsible for ensuring any of our studies are conducted in
compliance with protocols, regulations, and standards set by industry regulatory authorities and commonly referred to as current good
clinical practices (“cGCPs”) and good laboratory practices (“GLPs”). These required